These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 17401433)

  • 1. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
    Bullock AN; Henckel J; Fersht AR
    Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
    Müller P; Nenutil R; Vojtĕsek B
    Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
    Orgad S; Dimant H; Dor-On E; Azriel-Rosenfeld R; Benhar I; Solomon B
    J Immunother; 2010; 33(2):146-54. PubMed ID: 20139776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG
    Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of the transcription activation function to mutant p53 in human cancer cells.
    Abarzúa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A
    Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.
    Kakudo Y; Shibata H; Otsuka K; Kato S; Ishioka C
    Cancer Res; 2005 Mar; 65(6):2108-14. PubMed ID: 15781620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New transcription factor-based cancer therapy. Gene therapy, cell lysis, reactivation of p53 are the new approaches].
    Wiman KG
    Lakartidningen; 1997 Sep; 94(38):3268-72. PubMed ID: 9379794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific binding of MAR/SAR DNA-elements by mutant p53.
    Müller BF; Paulsen D; Deppert W
    Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [p53 as a molecular target for cancer therapy].
    Ishioka C; Osada M; Gamo M; Kanamaru R
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53: the loaded gun.
    Selivanova G
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1136-41. PubMed ID: 11892926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast.
    Grochova D; Vankova J; Damborsky J; Ravcukova B; Smarda J; Vojtesek B; Smardova J
    Oncogene; 2008 Feb; 27(9):1243-52. PubMed ID: 17724467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
    Sugikawa E; Tsunoda S; Nakanishi N; Ohashi M
    Anticancer Res; 2001; 21(4A):2671-5. PubMed ID: 11724337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.
    Vojtesek B; Dolezalova H; Lauerova L; Svitakova M; Havlis P; Kovarik J; Midgley CA; Lane DP
    Oncogene; 1995 Jan; 10(2):389-93. PubMed ID: 7530828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells.
    Karimi M; Conserva F; Mahmoudi S; Bergman J; Wiman KG; Bykov VJ
    Carcinogenesis; 2010 Jun; 31(6):1045-53. PubMed ID: 20427345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
    Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
    Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features.
    Walker DR; Bond JP; Tarone RE; Harris CC; Makalowski W; Boguski MS; Greenblatt MS
    Oncogene; 1999 Jan; 18(1):211-8. PubMed ID: 9926936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.